Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria:

* Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy.
* ECOG PS 0-1
* 70 years of age or older
* Must have measurable disease
* ANC \> 1500, platelets \> 100,000
* Total bilirubin \</= 1.5, SGOT \* SGPT \< 5 x ULN
* Able and willing to swallow and absorb oral medication
* Able and willing to sign consent
* Request archival diagnostic tissue for EGFR expression but not required

Exclusion Criteria:

* Proteinuria as demonstrated by UPC ratio \>/= 1.0
* Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide)
* Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic)
* History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation
* Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment.
* Current, ongoing treatment with full dose warfarin or equivalent
* Current(within 10 days)use of aspirin (\> 325mg/day) or other NSAID with antiplatelet activity
* History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD
* Known CNS disease except for treated brain mets.
* Squamous cell histology
* Blood pressure \> 150/100 that cannot be ameliorated with standard anti-hypertensives
* History of hypertensive crisis or hypertensive encephalopathy
* NYHA grade II or \> CHF
* History of MI within 6 months of enrollment
* Major surgery, open biopsy, significant trauma within 28 days of enrollment
* Pregnancy, lactation
* Abdominal or other fistula, abcess, perforation